WN
VRTX icon

Williams & Novak’s Vertex Pharmaceuticals VRTX Stock Holding History

Williams & Novak’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-687
Closed -$277K – 148
2024
Q4 		$277K Buy
+687
New +$318K 0.27% 85

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Williams & Novak's VRTX Position: Q1 2025 in Review

Williams & Novak sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 687 shares — an estimated $277K sold.

Williams & Novak first reported a position in VRTX in Q4 2024 and held it in 1 quarter. The position peaked at $277K in Q4 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Williams & Novak reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Williams & Novak sold 687 Vertex Pharmaceuticals shares in Q1 2025, an estimated $277K.
  • Williams & Novak first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Williams & Novak's Vertex Pharmaceuticals position peaked at $277K in Q4 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Williams & Novak's 13F filing for Q1 2025, filed 15 May 2025.